{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:01:28Z","timestamp":1789664488364,"version":"4.0.1"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ymgmr.2019.100454","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T11:05:40Z","timestamp":1549796740000},"page":"100454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts"],"prefix":"10.1016","volume":"19","author":[{"given":"Dominique P.","family":"Germain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor V.","family":"Fomin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Namdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o-Paulo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Viana-Baptista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2019.100454_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000060194","article-title":"A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant","volume":"136","author":"Germain","year":"2001","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0035","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0040","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0050","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front Cardiovasc. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0065","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/hrt.2010.211789","article-title":"Electrocardiographic changes in early recognition of Fabry disease","volume":"97","author":"Namdar","year":"2011","journal-title":"Heart."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0075","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0080","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0090","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4 Suppl","key":"10.1016\/j.ymgmr.2019.100454_bb0100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1590\/S1415-47572012000600009","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis","volume":"35","author":"Alegra","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0105","series-title":"Enzyme replacement therapy in Fabry disease \u2013 Methodology of a systematic literature review by a European panel of experts","author":"Elliott","year":"2019"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0110","unstructured":"Germain DP, Arad M, Burlina A, et al., The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease \u2013 a systematic literature review by a European panel of experts Mol. Genet. Metab., 2018, [accepted]."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0115","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","author":"Spada","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"Expert consensus statement on therapeutic goals in Fabry disease","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0125","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/GIM.0b013e318133fb1b","article-title":"The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"9","author":"Clarke","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0130","first-page":"7","article-title":"Effect and tolerability of agalsidase alfa in patients with Fabry disease who were treatment na\u00efve or formerly treated with agalsidase beta or agalsidase alfa","volume":"23","author":"Goker-Alpan","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0135","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S80928","article-title":"Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease","volume":"9","author":"Gol\u00e1\u0148","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","article-title":"CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy","volume":"27","author":"Jardim","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0155","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10545-006-0339-3","article-title":"Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease","volume":"29","author":"Jardim","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0160","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.2003.tb00220.x","article-title":"Head-impulse testing in Fabry disease--vestibular function in male and female patients","volume":"92","author":"Palla","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0175","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfm096","article-title":"Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease","volume":"22","author":"Pastores","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0180","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0185","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0200","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","article-title":"A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease","volume":"38","author":"Schiffmann","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0205","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0210","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1468-3083.2003.00831.x","article-title":"Fabry disease: enzyme replacement therapy","volume":"17","author":"Bongiorno","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0225","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-8-41","article-title":"Skin-impedance in Fabry disease: a prospective, controlled, non-randomized clinical study","volume":"8","author":"Gupta","year":"2008","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0230","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0235","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy - a retrospective analysis from the Fabry Outcome Survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0245","doi-asserted-by":"crossref","unstructured":"Kampmann C, Perrin A, Beck M, Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet. J. Rare. Dis. 10 (2015) 125. doi: 10.1186\/s13023-015-0338-2. doi: https:\/\/doi.org\/10.1186\/s13023-015-0338-2. [Erratum in: Orphanet. J. Rare. Dis. 11 (2016) 95.]","DOI":"10.1186\/s13023-015-0338-2"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0250","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease","volume":"67","author":"Kaneski","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0255","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jcma.2013.11.006","article-title":"Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa","volume":"77","author":"Lin","year":"2014","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0260","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0265","first-page":"87","article-title":"Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy","volume":"30","author":"Sergi","year":"2010","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0280","first-page":"191","article-title":"Fabry disease in an oligosymptomatic male","volume":"13","author":"Altarescu","year":"2011","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0285","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005078","article-title":"Paradoxical response to enzyme replacement therapy of fabry disease cardiomyopathy","volume":"9","author":"Frustaci","year":"2016","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0290","first-page":"17","article-title":"Carpal tunnel syndrome in Fabry disease","volume":"2","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000336168","article-title":"Phenotype and genotype characterization and twin association in patients with Anderson-Fabry cardiomyopathy","volume":"121","author":"Gomez","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0300","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1399-0004.2012.01916.x","article-title":"Successful long-term enzyme replacement therapy in a young adult with Fabry disease","volume":"83","author":"Kampmann","year":"2013","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0305","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1600-6143.2008.02245.x","article-title":"Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era","volume":"8","author":"Karras","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0310","first-page":"109","article-title":"Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0315","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.nefro.2015.08.001","article-title":"Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression","volume":"35","author":"Paliouras","year":"2015","journal-title":"Nefrologia."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0320","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.113.002799","article-title":"Progression of Fabry cardiomyopathy despite enzyme replacement therapy","volume":"128","author":"Pieroni","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cge.12673","article-title":"Gastrointestinal involvement in Fabry disease. So important, yet often neglected","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0330","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2169\/internalmedicine.54.4437","article-title":"A Patient with the GLA p.E66Q mutation exhibiting vascular parkinsonism and bilateral pulvinar lesions","volume":"54","author":"Tomizawa","year":"2015","journal-title":"Intern. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0335","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5414\/CNP69445","article-title":"Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy","volume":"69","author":"Torra","year":"2008","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2015.10.140","article-title":"Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy","volume":"203","author":"Yano","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0345","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0350","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0355","first-page":"95","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0360","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152812","article-title":"One Year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0370","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy","volume":"85","author":"Banikazemi","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0380","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0385","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","article-title":"Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry","volume":"119","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0395","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes","volume":"61","author":"Kim","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0400","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0405","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0410","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0415","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ymgme.2015.11.014","article-title":"Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort","volume":"117","author":"Arends","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0425","doi-asserted-by":"crossref","first-page":"260","DOI":"10.20452\/pamw.148","article-title":"Clinical stability of Fabry disease in 54 months\u2019 enzyme replacement therapy--follow-up of the first Polish study [in Polish]","volume":"117","author":"Bazan-Socha","year":"2007","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0430","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.athoracsur.2008.06.023","article-title":"Fabry disease with aortic regurgitation","volume":"87","author":"Choi","year":"2009","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0435","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/18.1.33","article-title":"Enzyme replacement therapy in Anderson-Fabry\u2019s disease: beneficial clinical effect on vital organ function","volume":"18","author":"De Schoenmakere","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0440","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1468-3083.2009.03455.x","article-title":"Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?","volume":"24","author":"Fauchais","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0445","doi-asserted-by":"crossref","first-page":"550","DOI":"10.5414\/CNP71550","article-title":"Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry\u2019s disease","volume":"71","author":"Hirashio","year":"2009","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0450","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1259\/bjr\/52065763","article-title":"Cardiac magnetic resonance imaging illustrating Anderson-Fabry disease progression","volume":"83","author":"Imbriaco","year":"2010","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0455","first-page":"7","article-title":"Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in Fabry disease?","volume":"7","author":"Moura","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0460","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5812\/nephropathol.8123","article-title":"A renal variant of Fabry disease: a case with a novel Gal A hemizygote mutation","volume":"1","author":"Mukdsi","year":"2012","journal-title":"J. Nephropathol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0465","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0470","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0475","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000351516","article-title":"Initially nondiagnosed Fabry\u2019s disease when electron microscopy is lacking: the continuing story of focal and segmental glomerulosclerosis","volume":"3","author":"Trimarchi","year":"2013","journal-title":"Case Rep. Nephrol. Urol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0480","doi-asserted-by":"crossref","unstructured":"Trimarchi H, Forrester M, Lombi F, et al., Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease: the potential roles of plasmin and uPAR. Case Rep. Nephrol. 2014 (2014) 854521. doi: https:\/\/doi.org\/10.1155\/2014\/854521","DOI":"10.1155\/2014\/854521"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0485","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/00015550410030682","article-title":"Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up","volume":"84","author":"Tsambaos","year":"2004","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0490","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/147323000703500418","article-title":"Enzyme replacement therapy in patients with Fabry\u2019s disease","volume":"35","author":"Tsuboi","year":"2007","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0495","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2008.12.028","article-title":"Amelioration of white-matter lesions in a patient with Fabry disease","volume":"279","author":"Yamadera","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0500","first-page":"33","article-title":"Effect of reduced agalsidase beta dosage in Fabry patients: the Australian experience","volume":"3","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0510","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0515","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0520","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ckj\/sfs114","article-title":"Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease","volume":"5","author":"Fujii","year":"2012","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0525","first-page":"282487","article-title":"Long-term effect of enzyme replacement therapy with Fabry disease","volume":"2013","author":"Komori","year":"2013","journal-title":"Int. J. Otolaryngol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0530","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0535","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"M. Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0540","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/ndt\/gfw334","article-title":"Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease","volume":"32","author":"Lenders","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0545","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003146","article-title":"Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)","volume":"3","author":"Lin","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0550","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0555","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10545-011-9428-z","article-title":"Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients","volume":"35","author":"Nicholls","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0560","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0565","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/heartjnl-2015-308897","article-title":"The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy","volume":"102","author":"Schmied","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0570","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0575","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10545-014-9783-7","article-title":"Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy","volume":"38","author":"Suntjens","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0580","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"Talbot","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0585","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1529-8027.2011.00365.x","article-title":"Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy","volume":"16","author":"\u00dc\u00e7eyler","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0590","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.012","article-title":"Cerebral hemorrhage in a paucisymptomatic young patient with Fabry disease","volume":"22","author":"Di Lazzaro","year":"2013","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0595","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-0500-7-11","article-title":"De novo mutation in a male patient with Fabry disease: a case report","volume":"7","author":"Iemolo","year":"2014","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0600","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2169\/internalmedicine.49.3724","article-title":"Fabry disease exhibiting recurrent stroke and persistent inflammation","volume":"49","author":"Kikumoto","year":"2010","journal-title":"Intern. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0605","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3904\/kjim.2015.30.6.925","article-title":"Fabry disease previously diagnosed as Henoch-Schonlein purpura","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0610","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/hrt.2003.023903","article-title":"Improvement of cardiac hypertrophy and ventricular function in a man with Fabry disease by treatment with recombinant alpha-galactosidase A","volume":"90","author":"Komamura","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0615","doi-asserted-by":"crossref","first-page":"e0143940","DOI":"10.1371\/journal.pone.0143940","article-title":"Positron emission tomography and magnetic resonance imaging of the brain in fabry disease: a nationwide, long-time, prospective follow-up","volume":"10","author":"Korsholm","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0620","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2369-14-6","article-title":"The coincidence of IgA nephropathy and Fabry disease","volume":"14","author":"Maixnerov\u00e1","year":"2013","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0625","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/cge.12590","article-title":"Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations - different outcome?","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0630","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijcard.2015.01.001","article-title":"A patient with recurrent disabling atrial fibrillation and Fabry cardiomyopathy successfully treated with single ring pulmonary vein isolation","volume":"182","author":"Qian","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0635","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cge.12261","article-title":"Intrafamilial phenotypic variability in four families with Anderson-Fabry disease","volume":"86","author":"Rigoldi","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0640","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jocn.2014.07.021","article-title":"A male Fabry disease patient treated with intravenous thrombolysis for acute ischemic stroke","volume":"22","author":"Saarinen","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0645","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.eye.6702517","article-title":"Fabry disease manifesting as chronic uveitis--treated with enzyme replacement therapy","volume":"21","author":"Shen","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0650","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/ndt\/gfw094","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"5","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0655","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s10157-011-0486-1","article-title":"Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new \u03b1-galactosidase mutation of Leu311Arg (L311R)","volume":"15","author":"Suzuki","year":"2011","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0660","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0665","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/gim.2014.28","article-title":"Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1","volume":"16","author":"Tsuboi","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0670","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2003.tb00217.x","article-title":"Hearing improvement in patients with Fabry disease treated with agalsidase alfa","volume":"92","author":"D","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0675","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2013.04.015","article-title":"A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"109","author":"Hughes","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0680","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-282X2006000500002","article-title":"White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up","volume":"64","author":"Jardim","year":"2006","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0685","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0690","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1651-2227.2003.tb00219.x","article-title":"Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females","volume":"92","author":"Conti","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0695","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","article-title":"Kidney transplantation in patients with Fabry disease","volume":"22","author":"Cybulla","year":"2009","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0700","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/B:BOLI.0000037342.59612.69","article-title":"Erratum: Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease","volume":"27","author":"Dehout","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0705","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1651-2227.2003.tb00214.x","article-title":"Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data","volume":"92","author":"Dehout","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0710","first-page":"437","article-title":"Cystatin C as a marker of early changes of renal function in Fabry nephropathy","volume":"20","author":"Feriozzi","year":"2007","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0715","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1750-1172-9-96","article-title":"Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A)","volume":"4","author":"Hsu","year":"2014","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0720","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0725","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00415-007-0575-y","article-title":"Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy","volume":"254","author":"Palla","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0730","first-page":"77","article-title":"Enzyme replacement therapy and renal function in 201 patients with Fabry disease","volume":"66","author":"Schwarting","year":"2006","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0735","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","article-title":"Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience","volume":"31","author":"Thofehrn","year":"2009","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0740","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0745","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0750","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0755","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0760","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-\u03b2","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0765","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0770","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0775","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0780","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0785","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0790","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0795","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0800","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3346\/jkms.2008.23.2.243","article-title":"Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease","volume":"23","author":"Choi","year":"2008","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0805","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1741826710391118","article-title":"Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease","volume":"19","author":"Collin","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0810","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0815","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0820","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"Imbriaco","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0825","first-page":"7","article-title":"Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase beta","volume":"16","author":"Juan","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0830","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0835","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2011.03.023","article-title":"MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease","volume":"160","author":"Koeppe","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0840","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10545-008-0848-3","article-title":"Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters","volume":"31","author":"Koskenvuo","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0845","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/eurjhf\/hfq211","article-title":"Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A","volume":"13","author":"Machann","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0850","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy","volume":"117","author":"Messalli","year":"2012","journal-title":"Radiol. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0855","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.echo.2011.05.021","article-title":"Tei index in Fabry disease","volume":"24","author":"Niemann","year":"2011","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0860","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0865","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry\u2019s disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0870","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0875","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0880","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0885","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0890","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0895","first-page":"41","article-title":"Effects of switching from agalsidase beta to agalsidase alfa in 10 patients with Anderson-Fabry disease","volume":"9","author":"Pisani","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0900","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0905","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch","volume":"25","author":"Weidemann","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0910","first-page":"1221.e1","article-title":"Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0915","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000879","article-title":"Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data","volume":"2","author":"Engelen","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0920","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ejechocard\/jen129","article-title":"Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy","volume":"9","author":"Kovacevic-Preradovic","year":"2008","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0925","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0930","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","article-title":"Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy","volume":"23","author":"Mignani","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0935","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0940","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfu273","article-title":"Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study","volume":"30","author":"Pisani","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0945","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gim.2012.39","article-title":"Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)","volume":"14","author":"Tsuboi","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0950","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MEG.0b013e32800fef46","article-title":"A diagnosis of Fabry gastrointestinal disease by chance: a case report","volume":"19","author":"Feriozzi","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0955","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0960","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0965","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2016.11.364","article-title":"PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study","volume":"120","author":"Warnock","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0975","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0980","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100454_bb0985","doi-asserted-by":"crossref","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2019.100454_bb0990","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426919300096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426919300096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:50:23Z","timestamp":1762001423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426919300096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":198,"alternative-id":["S2214426919300096"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100454","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100454"}}